Close Menu

NEW YORK (GenomeWeb) – A recently published study has demonstrated the ability of Genomind's Genecept pharmacogenetic test to reduce utilization of healthcare services and related costs among patients with mental illness, adding further clinical utility evidence that the company hopes will sway payors and drive adoption among psychiatrists.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.